Yes the price per indication would be different as the number of cycles can be different, but it is rare outside of sarcoma to go past 4 cycles these days because of the cardiotoxicity risk.
The estimate in the Triangle report is pretty conservative - to give you an example, G1 Therapeutics' Cosela has a list price of $US32K per chemo cycle and it provides no anticancer efficacy, just some (limited) protection from myleosupression.
Ann: Race releases complete cardio-protection data & video, page-227
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.040(2.42%) |
Mkt cap ! $267.8M | |||
| Open | High | Low | Value | Volume |
| $1.71 | $1.71 | $1.54 | $370.9K | 232.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 392 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.61 | 13999 | 1 |
View Market Depth
| Last trade - 16.10pm 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.58 |
Change
-0.040 ( 6.08 %) |
||||
| Open | High | Low | Volume | ||
| $1.62 | $1.65 | $1.54 | 41933 | ||
| Last updated 15.58pm 15/05/2024 ? | |||||
| RAC (ASX) Chart |